Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade<sup>®</sup> to Remsima<sup>®</sup>? An Observational Study.

Front Med (Lausanne) · 2020 · PMC7424016 · PMID 32850911

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

almost significantno p-value reported

The NOR-SWITCH study demonstrated that there was an almost significant difference for recurrent disease in CD, which is also proposed to be a granulomatous disorder, after patients were switched from Remicade ® to Remsima ® .

also in 1,858 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.